126 related articles for article (PubMed ID: 38372205)
1. Highly Sensitive Detection of T790 M with a Three-Level Characteristic Current by Thymine-Hg(II)-Thymine in the α-Hemolysin Nanopore.
Li Y; Yang Y; Zhong C; Xiao D; Zhou C
Anal Chem; 2024 Feb; 96(8):3587-3592. PubMed ID: 38372205
[TBL] [Abstract][Full Text] [Related]
2. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
3. High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation.
Tian P; Wang Y; Wang W; Li Y; Wang K; Cheng X; Tang Y; Han-Zhang H; Ye J; Chuai S; Li W
Lung Cancer; 2018 Oct; 124():205-210. PubMed ID: 30268462
[TBL] [Abstract][Full Text] [Related]
4. Early Monitoring Drug Resistant Mutation T790M with a Two-Dimensional Simultaneous Discrimination Nanopore Strategy.
Lei J; Huang Y; Zhong W; Xiao D; Zhou C
Anal Chem; 2020 Jul; 92(13):8867-8873. PubMed ID: 32452671
[TBL] [Abstract][Full Text] [Related]
5. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
[TBL] [Abstract][Full Text] [Related]
6. Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs.
Wang Z; Li X; Zhang L; Xu Y; Wang M; Liang L; Jiao P; Li Y; He S; Du J; He L; Tang M; Sun M; Yang L; Di J; Zhu G; Li L; Liu D
Cancer Med; 2021 May; 10(10):3323-3331. PubMed ID: 33932095
[TBL] [Abstract][Full Text] [Related]
7. Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study.
Wang Y; Wei Y; Ma X; Ma X; Gong P
Medicine (Baltimore); 2018 Jul; 97(28):e11346. PubMed ID: 29995771
[TBL] [Abstract][Full Text] [Related]
8. Sensitive detection of T790M mutations in lung cancer biopsies using a PCR-based lateral flow assay.
Dong N; Wang W; Lin S
Anal Biochem; 2022 Jan; 637():114476. PubMed ID: 34800430
[TBL] [Abstract][Full Text] [Related]
9. Probing mercury(II)-DNA interactions by nanopore stochastic sensing.
Wang G; Zhao Q; Kang X; Guan X
J Phys Chem B; 2013 May; 117(17):4763-9. PubMed ID: 23565989
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment.
Zhu L; Zhang S; Xun Y; Jiang Y; Xia B; Chen X; Wang L; Jiang H; Ma S
Pathol Oncol Res; 2018 Oct; 24(4):843-851. PubMed ID: 28868565
[TBL] [Abstract][Full Text] [Related]
11. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
Mambetsariev I; Vora L; Yu KW; Salgia R
BMC Cancer; 2018 Mar; 18(1):314. PubMed ID: 29562902
[TBL] [Abstract][Full Text] [Related]
12. Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.
Wang ZF; Ren SX; Li W; Gao GH
BMC Cancer; 2018 Feb; 18(1):148. PubMed ID: 29409466
[TBL] [Abstract][Full Text] [Related]
13. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
[TBL] [Abstract][Full Text] [Related]
14. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
[TBL] [Abstract][Full Text] [Related]
15. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
Lee K; Kim Y; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Choi YL; Sun JM
Lung Cancer; 2019 Apr; 130():87-92. PubMed ID: 30885357
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Idylla system to detect the EGFR
Bocciarelli C; Cohen J; Pelletier R; Tran Van Nhieu J; Derman J; Favre L; Bourgogne A; Monnet I; Chouaid C; Pujals A
Pathol Res Pract; 2020 Jan; 216(1):152773. PubMed ID: 31836323
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
Li X; Zhang D; Li B; Zou B; Wang S; Fan B; Li W; Yu J; Wang L
Lung Cancer; 2021 Jan; 151():39-43. PubMed ID: 33296806
[TBL] [Abstract][Full Text] [Related]
18. Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation.
Lee SH; Kim EY; Kim A; Chang YS
Cancer Biol Ther; 2020 Aug; 21(8):741-748. PubMed ID: 32543264
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Piotrowska Z; Niederst MJ; Karlovich CA; Wakelee HA; Neal JW; Mino-Kenudson M; Fulton L; Hata AN; Lockerman EL; Kalsy A; Digumarthy S; Muzikansky A; Raponi M; Garcia AR; Mulvey HE; Parks MK; DiCecca RH; Dias-Santagata D; Iafrate AJ; Shaw AT; Allen AR; Engelman JA; Sequist LV
Cancer Discov; 2015 Jul; 5(7):713-22. PubMed ID: 25934077
[TBL] [Abstract][Full Text] [Related]
20. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
